CD8A and metastatic melanoma: In a separate trial (NCT01159288), exosomes derived from autologous dendritic cells (DEX) were used as a therapeutic vaccine for patients with metastatic melanoma, indicating safety and tolerability, yet lacking strong responses from CD4+ or CD8+ T cells.